Investigated was Panax Ginseng potential preventative impact on Alzheimer's disease inflicted in rats. We used 90 rats, and we separated them into the following groups: Animals were administered oral Rivastigmine and Panax Ginseng (100 and 200 mg/kg/day, respectively) for two weeks, followed by a combination of each therapy for an additional four weeks, by management, an AD protection institution using AlCl3, third, fourth, and fifth agencies. The sixth group is a therapeutic AD group, whereas the seventh, eighth, and ninth groups are AD rats treated for 12 weeks with the same dosages of rivastigmine and panax ginseng. At baseline and after each treatment, behavioral stress tests, Rotarod and T-Maze tests were done. Rat brains were removed after each experiment and processed for histopathological analysis, acetylcholine (Ach) and acetycholinesterase (AchE) level measurements. According to this research, rats given AD showed reduced behavior, failed the Rotarod and T-Maze tests, had lower brain Ach levels, and had higher AchE levels. Rotarod and T-Maze tests revealed a substantial rise in brain Ach and a drop in AchE levels in rats treated with Rivastigmine and Panax ginseng in the protective and therapeutic groups, respectively. These findings, which were in line with histological studies, showed that Rivastagmine and Panax ginseng reduce the neurodegenerative symptoms of Alzheimer's disease in rats.